Skip to main content

Advertisement

Table 2 Objective responses

From: A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

2a. ITT on all enrolled patients
  Arm A (EV) (54)   Arm B (PLD/V) (50)  
  No. %   No. %  
CR 3 5.6 42.6% 8 16.0 52.0%
PR 20 37.0 42.6% 18 36.0 52.0%
NC 19 35.2   12 24.0  
PD 6 11.1   9 18.0  
2b. On evaluable patients
  Arm A (EV) (54)   Arm B (PLD/V) (47)  
  No. %   No. %  
CR 3 6.3 47.9% 8 17.0 55.3%
PR 20 41.6 47.9% 18 38.7 55.3%
NC 19 39.6   12 25.5  
PD 6 12.5   9 19.2  
2c. Overall response rates according to disease sites in evaluable patients (%)
  Arm A (EV) (48)   Arm B (PLD/V) (47)  
Soft tissue 66.6   77.7  
Bone 33.3   37.5  
Viscera 50.   53.3  
  1. Abbreviations: EV = epirubicin, vinorelbine; PLD/V = pegylated liposomal doxorubicin/vinorelbine; ITT = intent to treat; CR = complete response; PR = partial response; NC = no change; PD = progressive disease